Sitagliptin/Metformin Krka Filmuhúðuð tafla 50 mg/850 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sitagliptin/metformin krka filmuhúðuð tafla 50 mg/850 mg

krka, d.d., novo mesto - sitagliptinum inn; metforminum hýdróklóríð - filmuhúðuð tafla - 50 mg/850 mg

Sitagliptin/Metformin Medical Valley Filmuhúðuð tafla 50mg/850 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sitagliptin/metformin medical valley filmuhúðuð tafla 50mg/850 mg

medical valley invest ab - sitagliptinum hýdróklóríð; metforminum hýdróklóríð - filmuhúðuð tafla - 50mg/850 mg

Sitagliptin/Metformin Zentiva (Sitagliptin Metformin Zentiva) Filmuhúðuð tafla 50 mg/1000 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sitagliptin/metformin zentiva (sitagliptin metformin zentiva) filmuhúðuð tafla 50 mg/1000 mg

zentiva k.s.* - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50 mg/1000 mg

Sitagliptin/Metformin Zentiva (Sitagliptin Metformin Zentiva) Filmuhúðuð tafla 50 mg/850 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sitagliptin/metformin zentiva (sitagliptin metformin zentiva) filmuhúðuð tafla 50 mg/850 mg

zentiva k.s.* - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50 mg/850 mg

Sitagliptin / Metformin hydrochloride Sun Evrópusambandið - íslenska - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , þrefaldur samsetning meðferð) sem viðbót til að fæði og æfing í sjúklingar ekki nægilega stjórn á eigin hámarks þolað skammt af sjúklingar og sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.